Entech Electronics becomes Respiri’s global manufacturing partner for Wheezo

First orders for the wheezo have been placed and Entech Electronics commenced production preparation activities at their Shenzhen facility.

MELBOURNE: Respiri Limited, an eHealth SaaS Company supporting respiratory health management, announced a partnership with Entech Electronics for the global supply of the ground breaking wheezo.

Entech Electronics are an Australian, privately owned contract electronics manufacturer established in 1986. Headquartered in Devon Park, South Australia, the company has operated offshore production facilities in Shenzhen China since 2006.

With more than 34 years of experience in the electronic manufacturing space, relevant quality management systems and certifications in place, a product and customer portfolio that includes medical devices as well as aerospace and defence among others, Entech Electronics demonstrate both the capabilities and competencies required to meet the high quality and efficiency expectations Respiri have for the wheezo.

First orders for the wheezo have been placed and Entech Electronics commenced production preparation activities at their Shenzhen facility, an operation with more than 200 staff. 12,000 additional devices have been commissioned for delivery from February 2021 and this partnership will enable Respiri to scale production significantly and quickly so as to meet forecast global demand.

Owing to a range of design optimisation measures, relating to the device, its assembly, testing parameters and the cost reductions associated with moving to a low cost location, wheezo will enjoy a significantly improved product cost position and have reduced Cost of Goods by approximately 85% and these costs are forecast to fall further on the back of volume over time.

Marjan Mikel, Respiri’s CEO & Managing Director, commented: “We are delighted to partner with Entech Electronics as they are well placed to support our global product volume requirements at cost positions that support Respiri’s business model”.

Wayne Hoffman, CEO of Entech Electronics, added: “We are welcoming Respiri as a customer with significant growth potential and look forward to contributing to the success of wheezo with both our medical device experience and electronic manufacturing competence. Our operation in Shenzhen has commenced investment in assembly and test equipment that will allow us to scale quickly and react to Respiri’s forecast growing global demand and accommodate monthly volume requirements well in excess of 10,000 devices.”

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation.

wheezo, Respiri’s innovative technology, comprisesan eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals. Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.


About the author

Leave a Reply

Your email address will not be published.